HC Deb 05 February 1987 vol 109 cc815-6W
Mr. McNamara

asked the Secretary of State for Social Services how many of the manufacturing sites used by Harris Pharmaceuticals Ltd. for the production of generic medicines sold to the National Health Service were subject to inspection by the United Kingdom Medicines Inspectorate in each of the last three years; and when Harris Pharmaceuticals Ltd's manufacturing sites in South Africa were last inspected by the United Kingdom Medicines Inspectorate.

Mr. Newton

The manufacturing sites used by Harris Pharmaceuticals Ltd. for products for which it holds United Kingdom product licences are largely covered by multilateral agreements which provide for inspection reports to be supplied to the United Kingdom medicines inspectorate by the licensing authority of the country concerned. The remainder have been inspected by the

Northern Region
Income (£) Bad debts and claims abandoned (£)
Health Districts Section 58 Section 65 Section 66 Section 65 Section 66
Hartlepool 8,519 31,838 15,832 289
North Tees 1,377 33,341 9,842 397 86
South Tees 1,444 80,661 56,752
East Cumbria 92,332 15,124 13
South Cumbria 30 66,515 16,997 27
West Cumbria 9,646 1,619
Darlington 60,767 30,670
Durham 17,174 18,391 122
North West Durham 28,329 7,550 6 429
South West Durham 9,617 5,577 413
Northumberland 50,704 10,207 48
Gateshead 4,692 8,490 89 258

United Kingdom medicines inspectorate or are scheduled for a visit within the next 12 months. All South African manufacturing sites named as possible sources of supply for Harris Pharmaceuticals Ltd. were inspected by United Kingdom medicines inspectors in the last 16 months. The frequency of inspection is a matter for the licensing authority and details of dates of individual inspections are not normally disclosed.